Precision Biosciences (DTIL) Non Operating Investment Income (2021 - 2026)
Precision Biosciences' (DTIL) quarterly Non Operating Investment Income came in at -$3.0 million in Q1 2026, down 6122.45% year-on-year from $49000.0 in Q1 2025, and down 1089.92% on a QoQ basis from -$248000.0 in Q4 2025.
Precision Biosciences (DTIL) Non Operating Investment Income (2021 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 6 years of Non Operating Investment Income data on file, last reported at -$3.0 million in Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 6122.45% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$5.7 million, a 965.04% decrease from a year earlier, with the FY2025 full-year figure at -$2.7 million, down 1133.33% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$3.0 million, down from -$248000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for DTIL reached as high as $1.6 million in Q4 2023 and fell as low as -$3.0 million in Q1 2026.
- Historically, Non Operating Investment Income has averaged -$363384.6 across 5 years, with a median of -$248000.0 in 2025.
- Across the five-year window, Non Operating Investment Income jumped 414.31% in 2023 and sank 6122.45% in 2026, its largest moves.
- Year by year, Non Operating Investment Income stood at -$510000.0 in 2022, then soared by 414.31% to $1.6 million in 2023, then tumbled by 141.11% to -$659000.0 in 2024, then soared by 62.37% to -$248000.0 in 2025, then tumbled by 1089.92% to -$3.0 million in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$3.0 million in Q1 2026, -$248000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -248,000.00 |
| Dec 31, 2025 | -248,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | 49,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | -659,000.00 |
| Dec 31, 2024 | -659,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Mar 31, 2024 | -348,000.00 |
| Mar 31, 2024 | -348,000.00 |
| Dec 31, 2023 | 1.60 Mn |
| Dec 31, 2023 | 1.60 Mn |